Pfizer Announces Palbociclib More Than Doubled Progression-Free Survival in Phase 3 Trial for Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy

… factor receptor 2-negative (HER2-) metastatic breast cancer whose disease has progressed during … estrogen receptor-positive (ER+)/HER2- advanced breast cancer as initial endocrine-based therapy for … receptor 2-negative (ER+/HER2-) advanced breast cancer as initial endocrine-based therapy for …